---
category: news
title: "Data from First Phase III Clinical Study of PXT3003 in Charcot-Marie-Tooth ..."
excerpt: "PARIS, FRANCE / ACCESSWIRE / October 18, 2021 / Pharnext SA (FR0011191287 - ALPHA) (the 'Company'), an advanced late-stage clinical biopharmaceutical company pioneering new approaches to developing innovative drug combinations based on big genomics data and artificial intelligence using its PLEOTHERAPY(TM) platform,"
publishedDateTime: 2021-10-18T16:20:00Z
originalUrl: "https://www.pr-inside.com/data-from-first-phase-iii-clinical-study-of-pxt3003-in-charcot-marie-tooth-r4851276.htm"
webUrl: "https://www.pr-inside.com/data-from-first-phase-iii-clinical-study-of-pxt3003-in-charcot-marie-tooth-r4851276.htm"
type: article
quality: 20
heat: 20
published: false

provider:
  name: PR-Inside
  domain: pr-inside.com

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://www.pr-inside.com/images/logos/pr-inside/logo_pr-inside_fb.png"
    width: 1200
    height: 628
    isCached: true

secured: "YmjEOfH75HQ1D/dW9pu2k7sfq5qTHWmQGq9fD1Shy/d6JwT+Aj/7W1Khj65PDbLOPLTHwnS8+nzPesEkbB9/G6HAf5IqHr9Nbu/ZXg7fZtrdBoplQfEOoTPI7LkR6LcoSPagUS1SMTevXSyOjjrHOlamQjQyy90HB+suFfurjivctEPTUnw4TsAECUpMrCp+iPdm8LSmPV8rLpHcyOIo6IdWXiJ//oEMBUT8ZzV1vD3FqFmjSLGZzsskUzLf9HoWiD85mQ558X889JL8J6VDKq0H4kKBda86AedXaVfPcBO/Nf2d7MixsO9zEyCYRWGuMWVJpTI3+7VCvqOZqn0PbdSoXmP5KUR/TVUpkqaOeoo=;AKUvCrQIotAJgW1aHrjgKA=="
---

